UroGen Pharma Financial Ratios
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.83-0.15 (-0.41%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma ratio analysis
UroGen Pharma earned a net margin of -139.8% in FY 2025, up from -140.4% a year earlier. Gross margin was 88.7% compared with a median of 90.2% over the prior 9 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 9.95 | 5.32 | 5.23 | 3.14 | 4.42 | 33.26 | 36,358.66 | 718.72 | 44.32 | — |
| Price / book | — | — | — | — | 25.26 | 4.07 | 3.63 | 9.00 | 5.28 | — |
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% | 100.0% | -59.8% | 92.6% | 99.8% |
| Operating margin | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1,074.2% | -608,211.1% | -6,842.2% | -244.5% | 4.6% |
| Net margin | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% | -1,088.9% | -584,144.4% | -6,707.2% | -245.2% | -11.1% |
| Free cash flow margin | -148.2% | -107.4% | -92.6% | -136.4% | -178.3% | -907.7% | -396,344.4% | -3,359.4% | -120.6% | 19.9% |
| Return on equity (ROE) | — | — | — | — | -1,317.2% | -133.3% | -58.3% | -84.0% | -29.2% | -11.9% |
| Return on assets (ROA) | -76.6% | -44.4% | -57.3% | -80.9% | -92.5% | -105.3% | -52.0% | -73.1% | -26.5% | -8.4% |
| Debt / equity | — | — | — | — | 0.00 | — | — | — | — | — |
| Current ratio | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 | 5.39 | 7.63 | 7.59 | 10.59 | 7.03 |
| Revenue growth | 21.4% | 9.3% | 28.5% | 34.0% | 307.2% | 65,450.0% | -98.4% | -86.2% | -53.5% | — |